GSTM1 and neoplasm: Since measuring GSTM1 expression in additional tumor subtypes will allow us to determine if it is a common biomarker for recurrent meningiomas, we plan to analyze 14q-22q- and other subtypes of meningiomas in our future follow-up studies.